Sulphonamides and Folic Acid Antagonists in Malaria and Toxoplasmosis For many years the method of selection of new chemotherapeutic substances has been by trial and error. The empirical method is bound to remain of primary importance, but as knowledge of the processes of intermediate metabolism of the host and the parasite accumulates, it becomes possible to predict the chemical structure of substances likely to interfere.
Sulphonamides have quite powerful antimalarial activity, because they compete with p.AB. The metabolic chain from p.AB to folinic acid can therefore be interfered with at two points. If sulphonamide and pyrimethamine are given together to an animal infected with malaria, the effect is much greater than with either drug alone. The substances potentiate each other, because they block different parts of the same metabolic pathway. Fig. 1 shows this potentiation in Plasmodium gallinaceum malaria in chicks (Rollo, 1955) . At the most favourable combination of the two drugs, only 1/8th of the dose of pyrimethamine together with 1/7th of the dose of sulphadiazine are required to produce the effect given by either drug alone. Fig. 2 shows the effect of giving pyrimethamine and proguanil together. Both of these drugs act upon the folic-folinic acid system, and their effects are almost additive-the drugs certainly do not potentiate each other. Similarly, no potentiation is shown when pyrimethamine is given with chloroquine, a drug which has activity on a number of enzyme systems unrelated to the p.AB-folic acid series.
Although the potentiating action of sulphonamide and pyrimethamine has been known for some years, it has not yet been used in the treatment. of human malaria. It would be of interest to know what the action of the combination of drugs would be upon strains of the parasite which show resistance to proguanil and pyrimethamine. The potentiating effect of sulphonamides and pyrimethamine is also shown by other organisms which utilize the p.AB-folic acid metabolic chain. Eyles and Coleman (1952, 1953) working with experimental Toxoplasma infections in mice, found that this organism was resistant to all chemotherapeutic substances, except the sulphonamides, sulphones, diaminopyrimidines and aureomycin. The sulphones and aureomycin were of low activity, and the sulphonamides were little better. The most effective of a series of diaminopyrimidines was pyrimethamine, and potentiation was observed when pyrimethamine and sulphonamides were given together. The proportions of drug in the most effective combination were 1/25 of the dose of pyrimethamine and 1/8 of the dose of sulphadiazine which would show the same degree of activity as each given alone. Plasmodium gallinaceum (Rollo, 1955) . Ryan et al. (1954) gave pyrimethamine and sulphadiazine to 29 patients with acquired or congenital toxoplasmic chorioretinitis, carefully checked by tests of skin sensitivity to toxoplasmin and the presence of antibodies revealed by the dye test. Many had previously been treated by other methods without success.
Satisfactory clinical evidence of improvement was observed in 25 patients and 17 of them -showed siguificant clearing of vitreous opacities. The dose of pyrimethamine used was very large-75 to 100 mg. daily, with 0-5-15 grams of sulphadiazine for ten days. Such doses caused nausea and had an \-A effect upon haemopoiesis, and although -2 rapid recovery followed cessation of ED50 PYRIMETHAMINE (pg./kg.) treatment or reciuction OI tne aose, tins effect of pyrimethamine must be con -FIG. 2. -The effect of pyrimethamine and sidered when large doses are given. proguanil on P. gallinaceum in chicks (Rollo, Supplements of folic or, better, folinic 1955) . No affecting its action on the parasite. Petrovicky (1955) in Czechoslovakia also reports encouraging results upon 16 patients with positive tests for toxoplasma infection" Most of these had involvement of the nervous system, and sulphonamides and Aureomycin had failed to produce lasting improvement. Treated with pyrimethamine, 15 patients improved sufficiently to be able to return to work, although only one of the patients was given sulphonamides together with the pyrimethamine.
Smith and Perkins (1956) in London have also used pyrimethamine alone in the treatment of
toxoplasmic uveitis. As would be expected, the results, though encouraging, were not so striking as those obtained by workers who have used pyrimethamine with sulphonamides. Fig. 3 is a diagram of the metabolic pathway to the nucleoproteins. We the potentiation of sulphonamides and pyrimethamine on the p.AB-folinic acid system; they provide a useful selectively toxic combination against organisms which use this metabolic chain. In addition, the purine and pyrimidine antagonists, such as azaserine, azaguanine, bromouracil, and mercaptopurine, interfere with the utilization of purines and pyrimidines in the manufacture of nucleosides. Sulphonamides, pyrimethamine and these compounds show a series of progressive potentiations against susceptible strains of bacteria (Elion et al., 1954; Hitchings, 1955) . The purine and pyrimidine antagonists are active in neoplastic diseases, because they affect those cells which are most actively synthesizing nucleoprotein. They have no significant antimalarial action, and so far as I am aware, have not been tried in toxoplasmosis. Vitamin B,2 also plays a part in nucleoprotein synthesis (Arnstein, 1955) . Antagonists of vitamin B12 have been described by Lester Smith et al. (1956) and Cuthbertson et al. (1956) and may provide further stumbling-blocks to place in this metabolic pathway. There must be many possible sites of interference and drug potentiation, and our ignorance of them will be dispelled as the detailed picture of the chemistry of intermediate metabolism becomes clear (Brit. med. J., 1956) .
In general pharmacology potentiation between two drugs is most obvious when an enzyme which normally destroys one drug is inactivated by the potentiating drug as in the case of acetylcholine and the anticholinesterases. In chemotherapy we have, as yet, no knowledge of this type of action.
Most of the work on synergy has, so far, been purely empirical and has arisen from an examination of the behaviour of bacteria when exposed to antibiotics, while much useful knowledge has come from direct observations on patients themselves. While there are certain general rules for the combination of antibiotics, many of which rules have been elaborated by Jawetz and his colleagues, the only sure way to determine whether two agents are synergic in action is to try the effect of the combination on the rate of growth of the organism or on its complete destruction. As yet, biochemistry has contributed little of real significance but it seems possible that soon it will make a great contribution to practical chemotherapy. Thus synergy is to be expected if two or more agents were to block one pathway in the metabolism of an organism at successive points, for the result might be expected to be the product rather than the sum of the effects of the individual agents. This sequential blocking of the folic acid and folinic acid pathway is exemplified by the combined effect of pyrimethamine (Daraprim) and of sulphonamide on the malaria parasite and on coccidia respectively. The practical applications of this work may extend to a wide field of chemotherapy.
There may be another type of synergy in respect of those organisms which can develop a considerable resistance to a given antibiotic through their facility for adapting themselves to its action, particularly when prolonged treatment is necessary. In this type of synergy the two agents may be acting on different biochemical pathways; with a very potent substance like penicillin or streptomycin another will usually only be synergic if there is a tendency on the part of the organism to acquire resistance to the antibiotic. This resistance is probably due to the development of an alternative metabolic pathway or even to the organism adapting itself to the utilization of the antibiotic in place of its normal metabolite. There are many examples in bacterial chemotherapy. This type of synergic action is well known in its practical therapeutic applications as in the treatment of subacute infective endocarditis and of tuberculosis, but the biochemical implications are not yet understood.
In considering the problem of synergy in the treatment of malignant disease we have the possibility of a synergic effect in controlling the condition by the removal of one or more hormones which may help in delaying the growth of certain tumours. There is also great interest in any possible analogy between synergy as found in the treatment of infective disease and any possible synergy in the use of antimetabolite or antimytotic drugs for the treatment of malignant disease. This problem is vastly more difficult; for in infective disease we are attacking an actively multiplying invader which is in many respects different from the host cells, whereas in malignant disease we are attempting to differentiate between the malignant cell and other rapidly dividing cells of the body such as those of the bonemarrow or of the lining of the intestines. These cells in their normal activities are probably multiplying almost as rapidly as the malignant cells, and unless there are differences in their biochemistry, such as in the configuration or constitution of the nucleic acids, it is difficult to see how any chemotherapy can be effective without equivalent danger to the host. Nevertheless, there is some slight analogy with tuberculosis in that marked resistance is developed to nitrogen mustard, both in experimental tumours and in Hodgkin's disease.
In chemotherapy we have, as yet, little information of how the various agents produce their therapeutic effects but we are gaining some knowledge as to which will work best in combination with one another, and as the number of drugs increases we may find further opportunities for their combined application.
Dr. S. Brian Kendall, Veterinary Laboratory, Ministry of Agriculture, Weybridge:
Synergy between Pyrimethamine and Sulphonamides Used in the Control of Eimeria tenella
(1) The life-history of Eimeria tenella.-In addition to being an important pathogen of domestic fowls, Eimeria tenella is an unusually suitable subject for experimental investigation. The life-history follows a precise time-schedule, different developmental stages of the parasite appearing at predictable intervals and the clinical picture being characterized by sudden and violent hkmorrhage from the cxcum.
During the first 72 hours following the time of infection, the First Generation Schizonts develop superficially in the epithelium of the ceca, where they cause no evident damage. Between the 72nd and the 96th hour the Second Generation Schizonts develop more deeply in the submucosa and cause extensive tissue damage.
Between the 96th and 120th hours, rupture of the Second Generation Schizonts induces hamorrhage which is evinced by blood-stained faeces on the fifth and sixth days following infection. Following all but the lightest infection, a high rate of mortality can confidently be expected.
(2) The present use ofcoccidiostatic drugs.-During the past ten years several comparatively effective coccidiostatic drugs have been investigated. These include some of the sulphonamides of which sulphadimidine and sulphaquinoxaline have proved the most effective.
All drugs so far investigated, including the sulphonamides, appear to evince therapeutic activity through an inhibitory effect on the Second Generation Schizont, the growth of which is the only phase of the life-history known to be pathogenic to the chick.
At relatively low concentrations of drugs there is little apparent effect on stages which precede the Second Generation Schizont. At relatively high concentrations, however, stages other than the Second Generation Schizont may be affected.
It is important for satisfactory therapeutic control of disease not to exceed the minimum concentration of the drug which will suppress the Second Generation Schizonts.
(3) The efficacy of coccidiostatic drugs.-Although several of these drugs, in particular the sulphonamides, are proving effective for the control of caecal coccidiosis under practical conditions on the farm, their use can be criticized on the grounds that the concentrations necessary to control acute disease must be so high that some degree of inappetence is liable to be caused. In some circumstances, more definite evidence of toxicity is observed. In particular, the use of sulphaquinoxaline both in the field and in the laboratory has been associated with toxicity even at concentrations below those necessary to ensure full therapeutic control.
(4) The possibility of using drugs in synergic combinations.-The original observation of Lux (1954) that one of a group of 2, 4-diamino-pyrimidines, i.e. 2, 4-diamino, 5, p. chlorophenyl, 6-ethyl pyrimide-pyrimethamine (Daraprim), had a synergic effect on E. tenella when used in combination with certain sulphonamides, was, therefore, of outstanding interest.
At Weybridge we have confirmed and extended this observation of Lux with a view to developing effective systems of chemotherapy for the control of E. tenella in the field. Joyner and ; Kendall and Joyner (1956) .
(5) Efficacy of pyrimethamine and sulphadimidine in combination.- Fig. 1 demonstrates the effect of sulphadimidine and pyrimethamine, separately and together, on the rate of mortality in groups of chicks experimentally infected with Eimeria tenella. In each instance the drugs were given mixed with the food, treatment commencing on the morning of the second day following the day of infection and continuing until the morning of the fifth day.
It will be seen that a rate of mortality of 90 % was observed among chicks of the untreated (Control) Group (H). Sulphadimidine at a concentration in the food of 0 05% (Group C) had no effect on the rate of mortality. At a concentration of 0 1% of the food (Group D) there was a moderate effect (a reduction in the rate of mortality from 90% to 71 %). Pyrimethamine, at concentrations of 0 005 % (Group A) or 0-01 % (Group B) was rather : more effective. Even at 0 01 %, however, the reduction in the rate of mortality was only about 50%. When, however, the two drugs were-given together at the lower concentrations, i.e. 0-05 % sulphadimidine and 0-005 % pyrimethamine, there was complete control of the disease (Column G) and there was no mortality whatsoever.
(6) Further consideration of Fig. 1 .-In the first place it seems that the results recorded in columns E and F are anomalous in that the rates of mortality observed when sulphadimidine and pyrimethamine are used at concentrations of (01 % with 0-01 %) or (0'05 % with 0 01 %), are higher than with the lower concentrations used with Group G. It will be observed, however, that mortality with Groups E and F occurred on the ninth and tenth days following the day of infection (i.e. the fourth and fifth days following the termination of treatment), thus indicating a delay in the time of mortality of about four days as compared with that observed with the untreated disease.
This failure to control mortality, while delaying its onset by several days, has already been shown (Kendall and McCullough, 1952) to follow the use of sulphonamides given alone, i.e. without the synergic assistance of pyrimethamine, but at concentrations considerably higher than those ordinarily found necessary to inhibit the development of the Second Generation Schizonts.
It can be shown that excessive concentrations of the drugs cause marked but only temporary inhibition of the earlier developmental stages of the parasite and that the termination of a period of treatment is then followed by a resumption of development with haemorrhage and death.
(7) The effect-on different developmental stages of the parasite of high concentrations of sulphadimidine and pyrimethamine.-The different effects of the drugs on the different developmental stages of the parasite are well illustrated in Fig. 2 which shows the effects of high concentrations (0-4% sulphadimidine and 002% pyrimethamine) of the two drugs given together over periods of twenty-four hours on successive days following the time of infection, during the day of infection or for the day preceding infection. It will be observed that, as usual, the mortality in the group of untreated birds occurred principally on the fifth day following the day of infection. A period of twenty-four hours' treatment, covering the second, third or fourth days following the day of infection bad a marked therapeutic effect. Control of the disease was practically complete in Groups D and E and was partially effective (Group F) when treatment was delayed until the morning of the fourth day.
By contrast, treatment covering the day of infection, or the day following the day of infection, produced only temporary inhibition in the development of the parasite with no effect on the rate of mortality but a-marked effect on the time at which it occurred. Treatment which preceded the day of infection had some effect on the time at which mortality occurred, presumably as a result of the retention in the tissues of some of the drug.
(8) The effect of the drugs in combination is not a simple additive effect.-It might be deduced from. the experimental data in Fig. 1 that the combin6d effect of pyrimethamine and sulphadimidine was the result of potentiation rather than a simple additive effectfor it is shown that whereas neither 0 01 % pyrimethamine nor 0-l % sulphadimidine has a very marked effect, half the quantities of each of the drugs in combination produce full therapeutic control. This conclusion is confirmed by Fig. 3 which represents the relative proportions of pyrimethamine and sulphadimidine which together produce a 50% reduction in the rate of mortality.
If the effect were simply additive, then plotting the 50% inhibition doses should result in a straight line joining the point indicating inhibition with pure pyrimethamine with that indicating inhibition with pure sulphadimidine. It is shown, however, that 50% inhibition can be obtained using minimum amounts of the two drugs in combination which are less than a quarter of those required when using the drugs by themselves. The shape of the curve is very similar to that figured by Rollo (1955) when demonstrating the potentiation of sulphadiazine by pyrimethamine in the control of Plasmodium gallinaceum. This in itself suggests the possibility of a close analogy between the metabolism of E. tenella and those species of Plasmodium on which pyrimethamine and some sulphonamides exert a marked synergic effect.
Our work at Weybridge has, so far, supported the hypothesis that pyrimethamine and sulphadimidine act sequentially in a metabolic chain involving para-amino benzoic acid and folic or folinic acid.
The precise mechanisms involved are under investigation-by my colleague Dr. L. P.
Joyner who has been, throughout, associated with this work.
ACKNOWLEDGMENTS Thanks are due to the editors of the Journal of Comparative Pathology and Therapeutics (Kendall and Joyner, 1956b) for the loan of the block from which Fig. 3 has been printed and for permission to incorporate in Fig. 1 Synergism in Cancer Therapy In the treatment of cancer the main methods of treatment, surgery, radiotherapy and chemotherapy should be kept in mind. In the past these methods have most frequently been employed independently or sequentially, but the use of combined treatments is increasing. Chemotherapeutic agents as means of treating cancer can be grouped in four categories-hormones, antimetabolites, antibiotics and nitrogerr mustard derivatives which are alkylating agents.
In hormone therapy one might include the removal of glands as "negative hormone thera-py" or "negative chemotherapy" in which the sources of a hbrmone upon which the growth of tumours depends, are removed. Effective forms of negative hormonal chemotherapy include orchidectomy, oophorectomy, adrenalectomy and hypophysectomy used in the control of cancer of the prostate and cancer of the breast. These operations are not usually carried out simultaneously. Thus, in some cases of breast cancer when oophorectomy has become ineffective, adrenalectomy frequently produces successful remissions. If the growth then recurs, hypophysectomy or pituitary ablation by introducing radioactive gold under radiographic control as developed by Mr. W. P. Greening and Dr. J. J. Stevenson may be performed with success. Now these operations are usually performed in sequence rather than simultaneously and each operation may give a term of useful life. As these forms of surgical treatment are not to be undertaken lightly it is probable that they should not be carried out simultaneously except perhaps for oophorectomy and adrenalectomy. If, however, the operations of adrenalectomy and pituitary ablation and the after-care of patients could be simplified then they might be performed within a short time of each other with advantage.
The rationale of the operations of castration, adrenalectomy and hypophysectomy in cancer treatment is founded upon the fact that the growth of tumours is dependent on the presence of circulating hormones. If a tumour is dependent on the presence of sex hormones, then castration may restrict the growth by removing the sources of such hormones. In the absence of the gonads, however, the adrenals may elaborate sex hormones and so permit tumour growths. It was for this reason that Dr. Charles Huggins introduced adrenalectomy. Now if castration and adrenalectomy are performed together the hormones' deprivation might be more complete, so that the host defence mechanisms would have a better chance of destroying the neoplasm. There is also the possibility that some cancers require adrenal hormones for growth.
There are indications that cancers are either genetically unstable or readily adaptable so that in the absence of sex hormones they may become independent of such hormones.
When this happens the beneficial effect of the original operation is lost. The development of this independence might be delayed if the operations were performed at the same time because the independence may be acquired by mutation of the cancer cells. If the independence to each of two hormones is controlled by separate genes then the chance of a cancer cell arising which is independent of both hormones is very much less than if only one hormone were involved.
Some tumours may be unable to grow in the absence of hormones other than the sex hormones such as prolactin (mammatrophin), growth hormone or one of the other hormones produced by the hypophysis. It is also possible that the growth of tumours dependent on hormones elaborated by the adrenals may be controlled by removal of ACTH which might, in turn, control adrenal function. There is thus the possibility that some cancers of the breast and of the prostate may be dependent both on steroid hormones elaborated by the gonads or adrenals and on one or other of the pituitary hormones. In such caEes the chance of independent cancer cells arising is probably much reduced if the gonads, adrenals and pituitary are removed at an early stage of the disease, if independence to steroid hormones or pituitary hormones develop independently. If tumour cells become independent of steroid hormones then they will grow if the necessary pituitary hormone is present. If neither the steroid nor pituitary hormones are present then the possibility of hormone independent cancer cells arising is much reduced.
Chemotherapy is widely used in the handling of leukTmias and lymphadenopathy and, for these, synergic treatment should have advantages. Many cases of acute leukimia benefit from treatment with 6-mercapto-purine (an anti-purine drug), with amethopterin (an antifolic compound) and with ACTH or cortisone. Eventually, resistance develops to all these drugs and by analogy with the results obtained in chemotherapy of infectious diseases one might expect better results if combined treatment were used. Two of these forms of treatment-amethopterin and ACTH or cortisone-are so toxic that they cannot be used continuously for very long. In this form of therapy of acute leukemia combined treatment, which should reduce the incidence of drug resistance, must wait until other drugs which are more effective and as non-toxic as 6-mercapto-purine are available. Until that time it is probably advisable to keep the anti-folic acid compounds and cortisone or ACTH for use in the terminal stages of the disease, although successful results have been obtained with combined use of 6-mercapto-purine and cortisone.
The situation in treatment of the chronic leukemia is similar to that with acute leukemia in that too few effective drugs are available. Myleran and urethane produce beneficial results in myeloid leukxmia but urethane cannot be tolerated for long periods.
Myleran is an extremely effective drug but patients become resistant and treatments with Myleran in combination with 6-mercapto-purine or with sodium arsenite should be worth consideration.
Many patients suffering from lymphocytic leukemia and from Hodgkin's disease are improved by medication with the aromatic nitrogen mustards, R 1048 (2-(bis-2-chloroethyl) naphthylamine) or better R 1348 (4-(bis-2-chloroethyl) aminophenylbutyric acid). Both these compounds like the aliphatic nitrogen mustards are alkylating agents and so, presumably, act by similar mechanisms so that there would seem to be no advantage in using them together. Combined treatment of lymphadenopathies with CB 1348 and radiotherapy is sometimes effective and would seem to be a rational procedure.
Synergistic treatment is urgently needed in the therapy of malignant disease. The alkylating agents, Myleran and the aromatic nitrogen mustards are mutagens and the malignant cells are probably genetically unstable cells. There are therefore optimum conditions for the development of resistant forms and this frequently occurs. Advance in treatment of the leukaemias and lymphadenopathies is likely to follow the discovery of drugs which are effective against these diseases while operating through different mechanisms than that of alkylation, so that they can be used in combination over long periods.
If the agents used are antimetabolites then the agents should block essential sequential processes of tumour metabolism, as suggested by Potter. Increasing knowledge of the metabolic processes of cancer and leukemic cells should lead to the discovery of effective anti-metabolites which, used in conjunction with known agents, might allow the control of neoplastic growths.
Professor Robert Knox: Drug Combinations in Treatment ofBacterial Infections There is a natural attraction about the idea that two good drugs must be better than one, and, as Jawetz and Gunnison (1953) have pointed out, much of the talk about synergism of antibacterial drugs contains no more precise idea than that. Many workers, however, have been dissatisfied with the vagueness of the terms used and, in addition, have been puzzled by examples which suggested that combinations of drugs, far from enhancing the benefits of the single drugs, might actually be harmful. Attempts therefore have been made to define more precisely the words synergism and antagonism. Jawetz has suggested several definitions. In one of these (Jawetz and Gunnison, 1953) , synergism is stated to occur when "the bactericidal rate of a drug combination is more rapid than that of twice the concentration of each single drug participating in the mixture".
Theoretically it seems to me that there can be no such thing as synergism. If two drugs A and B act on the same receptor in a susceptible cell then their combined effect can only be additive, not synergic. If they act on different receptors then their effect on a susceptible cell is different in kind, and therefore quantitative comparisons cannot strictly be made. To do so is rather like trying to express the power of a bishop and a knight in chess in either bishop or knight equivalents. Apparent synergism can be caused in many ways. In some cases a so-called synergic effect can be quite simply explained on a chemical or physical basis, or by a combination of physical and chemical agents. I should like to discuss a few examples. Amygdalin and emulsin are each separately non-toxic to rabbits, but together kill, because free hydrocyanic acid is liberated when the emulsin acts on the amygdalin. Iron and oxine (8-hydroxycquinoline) separately have little action on Staph. aureus but together are rapidly bactericidal and Albert et al. (1953) has suggested an interesting explanation of this. The amine spermine inhibits and kills tubercle bacilli but only in the presence of tissues containing the enzyme spermine oxidase (Dubos, 1951; Hirsch, 1953 Hirsch, , 1955 . Clinically, the effect of penicillin is greatly increased by the use of benemid which blocks the excretion of penicillin by the kidneys. As an example of apparent synergism between a physical and a chemical agent, we have shown (Knox and Collard, 1952) that a strain of B. cereus could grow well at 370 C. in concentrations of penicillin up to a hundred times greater than those which completely suppressed its growth at 42' C.-presumably because the adaptive enzyme penicillinase could be synthesized at 37' C., but not at 42' C. It may be said that none of these are examples of synergism. If that is true, then we should have to admit that synergism ceases to exist as soon as it is explained.
In medical bacteriology we must distinguish two types of effect of drugs (1) a direct effect on all the individual members of a bacterial culture and (2) a differential effect on different members of a population whereby those individuals which are resistant to one drug are successfully dealt with by another. I think it is fair to say that a drug combination which shows the second effect may not necessarily show the first. In medical bacteriology two outstanding examples of apparent "synergism" are in the combined action of antituberculous drugs such as isoniazid (I.N.H.), streptomycin and PAS and in the combined effect of streptomycin and penicillin on certain types of streptococci. It is not at all easy to distinguish the two types of effect, but it would seem that the effect of combined chemotherapy in tuberculosis is to be explained partly at least as due to a delay in the development of resistance, though certain drug combinations are much more bactericidal than single drugs. Even here it is not always easy to be certain that the two drugs are not killing different members of the population. As regards certain streptococci, it seems clear that penicillin and streptomycin have a greatly increased bactericidal action out of all proportion to the effeot of the single drugs. Klein and Schorr (1953) showed that synergism was most marked with combinations of drugs to which resistance developed most rapidly when they were used singly. Clinically, antituberculous drug combinations are most effective in precisely those types of tuberculosis in which development of clinical resistance is most marked when the drugs are used singly, for example, in chronic pulmonary tuberculosis.
It must be admitted that our present techniques for measuring synergism in vitro are unsatisfactory. Garrod (1953) has indicated the possible value of a simple test for the bactericidal efficiency of drug combinations and Stern and Elek (1955) have attempted to measure bactericidal effects of drug combinations by the use of Lederberg's ingenious replica plating technique. As regards the resistance delaying type of effect, it is possible by in vitro tests to show that resistance of M. tuberculosis to certain drugs can be delayed by drug combinations. We are at present investigating the value of semi-solid agar media for this purpose (Knox, 1955) .
There is, however, little doubt that we shall not get far along purely empirical lines. Pittillo and Foster (1954) have recently made an interesting approach and have shown that synergism could be predicted in pairs of drugs whose action was known to be reversed by the same metabolite.
One of the great difficulties is to distinguish between multiple effects on single bacterial cells and effects on different cells in a bacterial population. The study by De Lamater, Maaloe and others of morphological changes produced by anti-bacterial drugs is an attempt to investigate such effects at the cellular level by using the techniques of microscopic cytology (Spooner and Stocker, 1956) . In our own laboratory we have tried to eliminate difficulties caused by selection by investigating the effect of drug combinations on the respiration of washed suspensions of M. tuberculosis by Warburg's manometric technique (Meadow and Knox, 1956 ). Here we found some evidence that for example, streptomycin and isoniazid in concentrations which separately did not inhibit respiration showed a more than additive effect when combined. Albert (1951) says in his admirable book on Selective Toxicity "It follows from the various facts which we have just been reviewing that comparative biochemistry is, of all branches of science, the one that holds the master key for the logical discovery of selectively toxic agents." Professor A. Albert: In his wisdom, Professor Buttle lost no time in directing our thoughts to what is called "sequential blocking". There can be little doubt that this is one of the most effective mechanisms of synergy. Current biochemical studies make us visualize a growth factor (e.g. folinic acid) being gradually built up from components as it moves along a "production line", each stage of assembly being carried out by a different enzyme. What, then, is the arithmetic of sequential blocking? If we block the first enzyme to the extent of 90%, then only 10% of the partly completed factor reaches the second enzyme. If we are lucky enough to have discovered how to block the second enzyme also by 90% then only 1 % of the (still incomplete) factor emerges, and that is little enough.
But, it may be asked, why not simply use more of the first drug, and block the first enzyme by 100%? The answer is that the patient would probably die first. Pharmacologists are familiar with the exponential effect of drugs on tissues: a large increase in the drug concentration causes little extra response. This is, after all, only a special application of the familiar principle of adsorption from solution, which follows a hyperbolic curve: the Langmuir isotherm (Langmuir, 1916) . A simple and familiar example of this behaviour is the adsorption of acetic acid from water, in which it has been dissolved, on to grains of carbon suspended in the water. If it is desired to make twice as much acetic acid become adsorbed on the carbon, the solution may have to be made ten times stronger in acetic acid. Thus to increase enzyme blocking from 90 to 100% would usually call for a quite inordinate amount of the drug and so endanger the patient's life.
The other effective mechanism of synergy is to use a substance, preferably something that is pharmacologically inert, to prevent the drug from being wasted at what Veldstra (1948) calls "sites of loss".
When a drug is introduced into the body it usually has to penetrate several semi-permeable membranes before it reaches its target, the "receptor". For example, mepacrine given orally in malaria, has to penetrate the gut-blood barrier, the red-cell membrane, and possibly that of the parasite. At every stage the active drug is involved in an equilibrium with the following processes: (a) Storage, (b) Elimination, (c) Destruction, (d) Diffusion towards the receptor.
Concerning storage, this may be good (e.g. when it helps to maintain a constant bloodlevel in malaria), or bad (e.g. when a drug is given as a hypnotic to a bread-winner). In the latter case, storage is waste, and so are elimination (e.g. by the kidneys) and destruction.
Waste by storage often occurs in fat (liposoluble drugs) and in tissues rich in nucleic acid (cationic drugs). Working with plant growth-substances, Veldstra (1948) showed that simple analogues, having no growth-promoting action, could intensify tenfold the action of such substances as naphthylacetic acid, and that the analogues did this by saturating "sites of loss", which were lipoid in nature. He also explained in this way the remarkable activating effect of sesamin on pyrethrin in fly-sprays, a synergy born of the acute scarcity of pyrethrin during the Second World War.
Waste by excretion is controllable in the case of penicillin by the administration of benemid or caronamid, which block the particular elimination process in the kidneys.
Waste by destruction may soon be brought under control, following upon the brilliant experiments of Brodie and his colleagues in the National Heart Institute, Bethesda (Brodie, 1955) . These workers showed that a simple aromatic ester (SKF 525) potentiates such diverse drugs as hypnotics, analeptics and analgesics by inhibiting a set of enzymes (of the triphosphopyridine-nucleotide class) which exist in the microsomes of liver apparently to dispose of foreign chemicals (including amines derived from putrefaction in the bowels). These enzymes are capable of carrying out at least five different types of destructive chemical reaction. This otherwise inert substance, SKF 525, blocks these destructive enzymes, and allows the patient to have a much higher proportion of the administered dose than otherwise.
intern. Med., 90, 301) . The action of penicillin on this organism exhibits the zone phenomenon, the optimum concentration being 6 pg. per ml. This produces only an incomplete bactericidal effect, but if streptomycin be added, even in a concentration itself without action alone, the preparation is sterilized.
An effect of this type is not often essential for successful therapy, and it is doubtful whether many tests of combined action need be carried out in a clinical laboratory. When they have to be, simple diffusion methods such as that employing antibiotics in blotting paper strips at right angles, should probably not be depended on. Replica plates from such preparations give also some information about bactericidal action, but we have preferred for some years in my laboratory to test combined action in tubes of liquid media which are plated after overnight incubation to determine whether there has been a bactericidal as well as bacteriostatic effect. To test four main antibiotics in this way (penicillin, streptomycin, chloramphenicol and a representative of the tetracyclines) singly and in every possible combination, each in a single appropriate concentration, requires only ten tubes.
Dr. J. K. A. Beverley: Sulphadimidine, 4.4' diamino-diphenylsulphone, and pyrimethamine, are all anti-toxoplasma drugs. In the treatment of generalized toxoplasmosis in mice following intra-nasal instillation of the R.H. strain, the medium effective dose (M.E.D.) of sulphadimidine bringing about survival for twenty-eight days is 30 mg. % in the diet, while that of pyrimethamine is 5 mg.% in the diet. The most effective combination of those two drugs giving the same result, is 10 mg.% of sulphadimidine and 0 3 mg. % of pyrimethamine. There is a similar synergy between 4.4' diamino-diphenylsulphone and pyrimethamine, but not between sulphadimidine and the sulphone, only an additive effect.
Eyles using a different strain of Toxoplasma and a different route of inoculation showed that there was synergy between sulphadiazine and pyrimethamine using a ten-day survival as a basis of estimating the M.E.D.
We have found that the superiority of a combination of pyrimethamine with either of the other two drugs over any of the drugs alone. was even more marked when survival for a total of fifty-six days (twenty-eight days on treatment followed by twenty-eight days on normal diet) and then demonstration of freedom from the carrier state were taken as criteria of effectiveness. Treatment with these drugs will protect rabbits from the fatal effect of toxoplasma infection, but will not prevent local damage at the site of inoculation. When the skin is inoculated there is ultimate healing with only minor scarring, but when the anterior chamber of the eye is used, gross irreparable damage follows. This local damage can be minimized by the concurrent administration of cortisone, and there is ultimately perfect function. Cortisone, when given alone, has no effect.
